Oncocross Statistics
Total Valuation
Oncocross has a market cap or net worth of KRW 119.82 billion. The enterprise value is 103.86 billion.
Market Cap | 119.82B |
Enterprise Value | 103.86B |
Important Dates
The next estimated earnings date is Monday, November 10, 2025.
Earnings Date | Nov 10, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Oncocross has 12.02 million shares outstanding. The number of shares has increased by 15.69% in one year.
Current Share Class | 12.02M |
Shares Outstanding | 12.02M |
Shares Change (YoY) | +15.69% |
Shares Change (QoQ) | +0.23% |
Owned by Insiders (%) | 27.15% |
Owned by Institutions (%) | 11.05% |
Float | 6.60M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 115.40 |
PB Ratio | 6.98 |
P/TBV Ratio | 7.00 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -13.56 |
EV / Sales | 100.03 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -13.75 |
Financial Position
The company has a current ratio of 14.88, with a Debt / Equity ratio of 0.02.
Current Ratio | 14.88 |
Quick Ratio | 14.81 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | -0.05 |
Interest Coverage | -268.96 |
Financial Efficiency
Return on equity (ROE) is -49.39% and return on invested capital (ROIC) is -32.00%.
Return on Equity (ROE) | -49.39% |
Return on Assets (ROA) | -30.09% |
Return on Invested Capital (ROIC) | -32.00% |
Return on Capital Employed (ROCE) | -46.98% |
Revenue Per Employee | 33.49M |
Profits Per Employee | -247.14M |
Employee Count | 31 |
Asset Turnover | 0.06 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 9,707.60 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 53.74 |
Average Volume (20 Days) | 100,716 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncocross had revenue of KRW 1.04 billion and -7.66 billion in losses. Loss per share was -682.54.
Revenue | 1.04B |
Gross Profit | 758.82M |
Operating Income | -8.10B |
Pretax Income | -7.66B |
Net Income | -7.66B |
EBITDA | -7.59B |
EBIT | -8.10B |
Loss Per Share | -682.54 |
Balance Sheet
The company has 16.34 billion in cash and 373.60 million in debt, giving a net cash position of 15.96 billion or 1,328.20 per share.
Cash & Cash Equivalents | 16.34B |
Total Debt | 373.60M |
Net Cash | 15.96B |
Net Cash Per Share | 1,328.20 |
Equity (Book Value) | 17.16B |
Book Value Per Share | 1,436.06 |
Working Capital | 15.36B |
Cash Flow
In the last 12 months, operating cash flow was -6.47 billion and capital expenditures -1.08 billion, giving a free cash flow of -7.56 billion.
Operating Cash Flow | -6.47B |
Capital Expenditures | -1.08B |
Free Cash Flow | -7.56B |
FCF Per Share | -628.70 |
Margins
Gross Margin | 73.09% |
Operating Margin | -780.61% |
Pretax Margin | -737.92% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Oncocross does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -15.69% |
Shareholder Yield | n/a |
Earnings Yield | -6.39% |
FCF Yield | -6.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Oncocross has an Altman Z-Score of 61.72 and a Piotroski F-Score of 4.
Altman Z-Score | 61.72 |
Piotroski F-Score | 4 |